Showing results (1-10 of 116) with videos related to
Sort By:
Pageof 12
Biochemical Pharmacology|March 5, 2011
Exosomes as intercellular signalosomes and pharmacological effectorsMichel Record, Caroline Subra, Sandrine Silvente-Poirot, et al.Biochimie|July 6, 2013
Emerging concepts on the role of exosomes in lipid metabolic diseasesMichel Record, Marc Poirot, Sandrine Silvente-PoirotBiochimica Et Biophysica Acta|October 22, 2013
Exosomes as new vesicular lipid transporters involved in cell-cell communication and various pathophysiologiesMichel Record, Kevin Carayon, Marc Poirot, et al.Biochimie|June 6, 2016
From tamoxifen to dendrogenin A: The discovery of a mammalian tumor suppressor and cholesterol metaboliteSandrine Silvente-Poirot, Philippe de Medina, Michel Record, et al.Journal of Lipid Research|May 17, 2018
Extracellular vesicles: lipids as key components of their biogenesis and functionsMichel Record, Sandrine Silvente-Poirot, Marc Poirot, et al.Autophagy|September 5, 2022
Targeting NR1H/liver X receptor with dendrogenin A differentiates tumor cells to activate a new secretory pathway releasing immunogenic anti-tumor vesicles enriched in LC3-II-associated exosomesPhilippe de Medina, Julio Bunay, Marc Poirot, et al.Current Opinion in Pharmacology|August 25, 2012
Cholesterol epoxide hydrolase and cancerSandrine Silvente-Poirot, Marc PoirotBiochimie|May 23, 2012
Cholesterol-5,6-epoxides: chemistry, biochemistry, metabolic fate and cancerMarc Poirot, Sandrine Silvente-PoirotBiochemical Pharmacology|February 8, 2018
The tumor-suppressor cholesterol metabolite, dendrogenin A, is a new class of LXR modulator activating lethal autophagy in cancersMarc Poirot, Sandrine Silvente-PoirotBiochemical Society Transactions|April 13, 2016
When cholesterol meets histamine, it gives rise to dendrogenin A: a tumour suppressor metaboliteMarc Poirot, Sandrine Silvente-PoirotPageof 12